Stocklytics Platform
Asset logo for symbol APLS
Apellis Pharmaceuticals
APLS64
$26.27arrow_drop_down6.37%-$1.78
Asset logo for symbol APLS
APLS64

$26.27

arrow_drop_down6.37%

Performance History

Chart placeholder
Key Stats
Open$28.05
Prev. Close$28.06
EPS-2.02
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range26.02
28.39
52 Week Range24.35
73.80
Ratios
EPS-2.02

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals Inc. (APLS) is a biopharmaceutical company focused on the development and commercialization of novel therapeutic compounds for the treatment of autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan (APL-2), an investigational targeted C3 therapy. Pegcetacoplan is currently being evaluated in phase 3 clinical trials for the treatment of geographic atrophy (GA) and paroxysmal nocturnal hemoglobinuria (PNH).
Geographic atrophy is a progressive and irreversible form of age-related macular degeneration (AMD) that leads to the loss of central vision. There are currently no approved treatments for GA, and Apellis aims to address this unmet medical need with pegcetacoplan. The phase 3 trials for GA are ongoing, and if successful, pegcetacoplan could become the first FDA-approved therapy for this debilitating condition.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Cedric Francois M.D., Ph.D.
Headquarters
Waltham
Employees
767
Exchange
NASDAQ
add Apellis Pharmaceuticals  to watchlist

Keep an eye on Apellis Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Apellis Pharmaceuticals 's (APLS) price per share?

The current price per share for Apellis Pharmaceuticals (APLS) is $26.27. The stock has seen a price change of -$1.79 recently, indicating a -6.38% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Apellis Pharmaceuticals (APLS)?

For Apellis Pharmaceuticals (APLS), the 52-week high is $73.8, which is 180.93% from the current price. The 52-week low is $24.36, the current price is 7.85% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Apellis Pharmaceuticals (APLS) a growth stock?

Apellis Pharmaceuticals (APLS) has shown an average price growth of -6.65% over the past three years. It has received a score of 28 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Apellis Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Apellis Pharmaceuticals (APLS) stock price performance year to date (YTD)?

As of the latest data, Apellis Pharmaceuticals (APLS) has a year-to-date price change of -57.12%. Over the past month, the stock has experienced a price change of -6.01%. Over the last three months, the change has been -29.48%. Over the past six months, the figure is -37.45%. Looking at a longer horizon, the five-year price change stands at -5.57%.
help

Is Apellis Pharmaceuticals (APLS) a profitable company?

Apellis Pharmaceuticals (APLS) has a net income of -$528.63M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 84.82% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -24.02% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $396.59M, although specific revenue growth data is currently not available. The gross profit is $336.38M. Operating income is noted at -$517.12M. Furthermore, the EBITDA is -$221.51M.
help

What is the market capitalization of Apellis Pharmaceuticals (APLS)?

Apellis Pharmaceuticals (APLS) has a market capitalization of $3.27B. The average daily trading volume is 26.47, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level